全文获取类型
收费全文 | 503篇 |
免费 | 34篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 5篇 |
妇产科学 | 4篇 |
基础医学 | 18篇 |
口腔科学 | 3篇 |
临床医学 | 69篇 |
内科学 | 99篇 |
皮肤病学 | 2篇 |
神经病学 | 15篇 |
特种医学 | 88篇 |
外科学 | 33篇 |
综合类 | 24篇 |
预防医学 | 29篇 |
眼科学 | 11篇 |
药学 | 104篇 |
中国医学 | 5篇 |
肿瘤学 | 32篇 |
出版年
2022年 | 2篇 |
2021年 | 1篇 |
2020年 | 2篇 |
2019年 | 4篇 |
2018年 | 7篇 |
2017年 | 7篇 |
2016年 | 6篇 |
2015年 | 19篇 |
2014年 | 16篇 |
2013年 | 23篇 |
2012年 | 20篇 |
2011年 | 33篇 |
2010年 | 25篇 |
2009年 | 30篇 |
2008年 | 29篇 |
2007年 | 20篇 |
2006年 | 19篇 |
2005年 | 13篇 |
2004年 | 18篇 |
2003年 | 12篇 |
2002年 | 10篇 |
2001年 | 9篇 |
2000年 | 13篇 |
1999年 | 12篇 |
1998年 | 15篇 |
1997年 | 18篇 |
1996年 | 17篇 |
1995年 | 14篇 |
1994年 | 9篇 |
1993年 | 12篇 |
1992年 | 8篇 |
1991年 | 3篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 10篇 |
1987年 | 7篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 4篇 |
1983年 | 5篇 |
1982年 | 8篇 |
1981年 | 6篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1977年 | 7篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1971年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有541条查询结果,搜索用时 15 毫秒
1.
More than just crushing: a prospective pre‐post intervention study to reduce drug preparation errors in patients with feeding tubes
下载免费PDF全文
![点击此处可从《Journal of clinical pharmacy and therapeutics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
2.
Bergner Raoul; Hoffmann Martin; Riedel Klaus-Dieter; Mikus Gerd; Henrich Dirk M.; Haefeli Walter E.; Uppenkamp Michael; Walter-Sack Ingeborg 《Nephrology, dialysis, transplantation》2006,21(4):1019-1023
To cover intermediate sensitive Candida glabrata in ICU patients,fluconazole plasma peak levels at least in the range of 1632µg/ml appear necessary for treatment. Previous studiesdid not reach these fluconazole levels under continuous veno-venoushaemofiltration (CVVHF) with dosages of 200600 mg fluconzoledaily. In the present study, nine patients simultaneously requiringCVVHF for treatment of acute oligoanuric renal failure and antimycotictherapy of Candida septicemia received fluconazole 800 mg/day.Fluconazole plasma levels were determined to evaluate whetherthis dosage is adequate to reach the advised fluconazole levels.Patients were dialysed on two consecutive days with an ultrafiltrationrate (UF) of 1000 ml/h or 2000 ml/h, respectively, in a randomizedorder. The predilution was 800 ml/h and 1800 ml/h, respectively.The treatment was tolerated without adverse effects. All patientsreached plasma fluconazole concentrations between 16 and 32µg/ml, remaining in this range for a minimum of 1 up to24 h with a mean of 9.6 h and a UF rate of 2000 ml/h, and 15.7h with a UF rate of 1000 ml/h. So far, there are no in vivodata on the fluconazole plasma concentrations required for effectivetreatment. However, our data demonstrate, that at least thefluconazole concentrations desirable on the basis of in vitrosusceptibility testing can be reached in critically ill patientson CVVHF in an ICU setting. However, in these patients, 800mg fluconazole/day are necessary to achieve fungicidal drugconcentrations. 相似文献
3.
Leonidas JC; Berdon WE; Valderrama E; Neveling U; Schuval S; Weiss SJ; Hilfer C; Godine L 《Radiology》1996,198(2):377
4.
5.
6.
Normal and diseased isolated lungs: high-resolution CT 总被引:8,自引:0,他引:8
7.
Fuchs P Haefeli WE Ledermann HR Wenk M 《European journal of clinical pharmacology》1999,54(11):869-876
Objectives: To evaluate the in vivo effect of xanthine oxidase (XO) inhibition by allopurinol on the determination of polymorphic N-acetyltransferase 2 (NAT2) and cytochrome P450 1A2 (CYP1A2) with urinary caffeine metabolic ratios.
Methods: In an open, prospective study involving 21 healthy subjects (eight fast, 13 slow NAT2 acetylators) allopurinol (300 mg perday)
was administered orally on trial days 1–8, followed by a wash-out period of 8 days. Urinary caffeine tests (200 mg caffeine
p.o.) were performed repetitively. Urine was collected for 8 h and venous blood samples for the determination of allopurinol,
oxypurinol and uric acid were drawn. The urinary caffeine metabolites 1-methyluric acid (1MU), 1-methylxanthine (1MX), 1,7-dimethyluric
acid (17MU), 1,7-dimethylxanthine (17MX), 5-acetylamino-6-formylamino-3-methyluracil (AFMU), plasma allopurinol and oxypurinol
were analysed using high-performance liquid chromatography (HPLC).
Results: During XO inhibition by allopurinol, the formation of 1MU from 1MX and therefore the XO ratio 1MU/1MX decreased to 15.9
(1.2)% [mean with (SEM)] of baseline values (P < 0.005). The NAT2 ratio AFMU/1MX decreased likewise to 56.7 (6.3)% (P < 0.005). AFMU/(AFMU + 1MX + 1MU), an alternative NAT2 ratio, remained constant, but the CYP1A2 ratio (AFMU + 1MX + 1MU)/17MU,
used to express CYP1A2 activity, transiently increased to 167 (13)% (P < 0.005). The NAT2 phenotype did not influence CYP1A2 and XO ratios or plasma oxypurinol pharmacokinetics.
Conclusions: Several caffeine metabolic ratios are commonly used to express the activities of NAT2, CYP1A2 and XO both in healthy volunteers
and in polymedicated patients, although their reliability has not been evaluated thoroughly during concurrent drug administration.
The findings of this study suggest that NAT2 phenotyping should be performed using the ratio AFMU/(AFMU + 1MX + 1MU) if an
XO inhibitor may be present. It also shows that the determination of CYP1A2 activity with caffeine as a metabolic probe is
considerably altered under these conditions. Thus, concomitant drug administration may impair the robustness of multiple pathways
of the complex caffeine test. This points to the need for alternative probes, designed to assess only the activity of a single
enzyme because, in contrast to healthy volunteers, in patients known or unknown drug interactions may often be present.
Received: 10 August 1998 / Accepted in revised form: 5 October 1998 相似文献
8.
Andreas D Meid Anette Lampert Alina Burnett Hanna M Seidling Walter E Haefeli 《British journal of clinical pharmacology》2015,80(4):768-776
Aims
The aim of the present study was to conduct a meta-analysis of controlled trials assessing the impact of pharmaceutical care interventions (e.g. medication reviews) on medication underuse in older patients (≥65 years).Methods
The databases MEDLINE and EMBASE were searched for controlled studies, and data on interventions, patient characteristics and exposure, and outcome assessment were extracted. Risk of bias was assessed using the Cochrane Collaboration’s ‘risk of bias’ table. Results from reported outcomes were synthesized in multivariate random effects meta-analysis, subgroup meta-analysis and meta-regression.Results
From 954 identified articles, nine controlled studies, mainly comprising a medication review, were included (2542 patients). These interventions were associated with significant reductions in the mean number of omitted drugs per patient (estimate from six studies with 1469 patients: – 0.44; 95% confidence interval –0.61, –0.26) and the proportion of patients with ≥1 omitted drugs (odds ratio from eight studies with 1833 patients: 0.29; 95% confidence interval 0.13, 0.63). The only significant influential factor for improving success was the utilization of explicit screening instruments when conducting a medication review (P = 0.033).Conclusion
Pharmaceutical care interventions, including medication reviews, can significantly reduce medication underuse in older people. The use of explicit screening instruments alone or in combination with implicit reasoning is strongly recommendable for clinical practice. 相似文献9.
Coakley G; Mok CC; Hajeer AH; Ollier WE; Turner D; Sinnott PJ; Hutchinson IV; Panayi GS; Lanchbury JS 《Rheumatology (Oxford, England)》1998,37(9):988-991
OBJECTIVE: To examine whether promoter polymorphisms associated with
variation in interleukin-10 (IL-10) production are relevant to the
development of rheumatoid arthritis (RA) or Felty's syndrome (FS). METHODS:
DNA was obtained from 44 FS patients, 117 RA patients and 295 controls. The
promoter region between -533 and - 1120 was amplified by polymerase chain
reaction, and polymorphisms detected by restriction enzyme digest or
sequence-specific oligonucleotide probing. RESULTS: We found no significant
difference in allele or haplotype frequencies between the groups.
CONCLUSION: There is no association between FS or RA and these recently
identified IL-10 promoter polymorphisms. Other genetic or environmental
factors could explain the alterations in IL-10 levels seen in these
conditions.
相似文献
10.
Ether lipids (EL) and hyperthermia have been shown to possess a relatively selective cytotoxicity to leukemic cells. In this study, the combined effects of EL (ET-18-OCH3, ET-16-NHCOCH3, or BM 41.440) and hyperthermia on the growth of hematopoietic progenitors, myeloid leukemic cell lines, and leukemic cells obtained from patients with acute myeloid leukemia (AML) were examined to determine if this combination resulted in a greater selective killing of leukemic cells than that achieved by either EL or heat alone. When the cells were treated simultaneously with EL (50 micrograms/mL) and hyperthermia (42 degrees C) for one hour, the killing of leukemic cell line cells was enhanced considerably. Among the three EL, however, the combination of ET-18-OCH3 and heat seemed to be the most cytotoxic to leukemic cell line cells with no effect on the growth of hematopoietic progenitors. An increase in the duration of treatment with ET-18-OCH3 to four hours with heat added during the last hour resulted in a further reduction of leukemic cell line cells while sparing 50% of hematopoietic progenitors after cryopreservation. The combined treatment with ET-18-OCH3 and heat also inhibited the growth of leukemic progenitors obtained from AML patients by 97% to 100%. These data indicate that the combined treatment with EL and hyperthermia might offer an efficient means to eliminate myeloid leukemic cells in vitro. 相似文献